RxDoctor Payments Data

Elaine Engelsman, NP

Family · Muskegon, MINPI 1083822803

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $21,488 of the $27,376 with a category attached, or 78.5%. AbbVie accounts for 94.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $8,934 and has fallen 99.0% since, to $90 in 2025. Among family clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$27,376in general payments, 2019–2025

Across 126 payments — averaging $217.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$26K
  • Gilead$915
  • Viiv Healthcare Company$312
  • GSK$67
  • Merck$51
  • Johnson & Johnson$45
  • plus $70 from 3 others

What the payments were for

  • Speaking & faculty fees$21,48878%
  • Travel & lodging$3,39512%
  • Food & beverage$2,4949%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,376 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$1,989
Medicare patients
52
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpclusaSofosbuvir/Velpatasvir82$1,921,228
BiktarvyBictegrav/Emtricit/Tenofov Ala225$835,254
TivicayDolutegravir Sodium124$267,872
DescovyEmtricitabine/Tenofov Alafenam111$232,766
GenvoyaElviteg/Cob/Emtri/Tenof Alafen49$183,877
OdefseyEmtricitab/Rilpiviri/Tenof Ala45$148,902
PrezcobixDarunavir/Cobicistat36$84,316
CabenuvaCabotegravir/Rilpivirine13$68,237
Etravirine11$12,097
Dapsone11$320
Doxycycline Hyclate11$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadEpclusa, Biktarvy, Descovy, Genvoya$915$3,173,124467 claims
Viiv Healthcare CompanyTivicay, Cabenuva$312$336,108137 claims
Johnson & JohnsonPrezcobix$45$84,31636 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.

Other family in Muskegon

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →